Rare Disease Research: BIO Testifies on Accelerating Rare Disease Research and Orphan Product Development

We urged increased funding for the Orphan Drug Grant Program, the consideration of a longer U.S. exclusivity period, a more predictable regulatory approval pathway for orphan products, and additional guidance regarding orphan drug development. We supported alternative clinical trial designs and the use of surrogate clinical endpoints for studies of rare disease products.